Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGI-110 + Durvalumab + Tremelimumab in ES-SCLC
NCT03085849Phase 1Completed
- Start
- Dec 2017
- Primary completion
- Nov 2018
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of guadecitabine in small cell lung cancer (SCLC). Primary endpoint: Maximum Tolerated Dose of SGI-110. Started Dec 2017; status: completed.
02
Drugs
guadecitabine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03085849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085849.